Home > A. Molecular pathology > Signaling pathways > MAPK signaling pathway

MAPK signaling pathway

Wednesday 11 June 2003

MAPK Pathway

Members

ERK BRAF RAS MAPKs

MAPK pathway inhibitors

The MAPK pathway is a key therapeutic target for melanoma as it is activated in most tumors. Despite the clinical success of drugs targeting this pathway, their therapeutic efficacy is limited by the development of drug resistance. To develop effective therapies for melanoma, it is critical to uncover the mechanisms of resistance to BRAF inhibitors and MEK inhibitors. Recent studies on the molecular mechanisms of resistance to inhibitors of the MAPK pathway and potential strategies to overcome resistance will be discussed.

See also

- RASs: HRAS, KRAS, NRAS

References

- Kim IA, Fernandes AT, Gupta AK, McKenna WG, Bernhard EJ. The influence of Ras pathway signaling on tumor radiosensitivity. Cancer Metastasis Rev. 2004 Aug;23(3-4):227-36. PMID: #15197325#

- Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003 Jan;3(1):11-22. PMID: #12509763#

- Stork PJ, Schmitt JM. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol. 2002 Jun ;12(6):258-66. PMID : #12074885#

- Hazzalin CA, Mahadevan LC. MAPK-regulated transcription: a continuously variable gene switch? Nat Rev Mol Cell Biol. 2002 Jan;3(1):30-40. PMID: #11823796#

- Madhani HD, Fink GR. The riddle of MAP kinase signaling specificity. Trends Genet. 1998 Apr;14(4):151-5. PMID: #9594663#

- Breitkreutz A, Tyers M. MAPK signaling specificity : it takes two to tango. Trends Cell Biol. 2002 Jun ;12(6):254-7. PMID : #12074884#

Portfolio

  • Signal-transduction pathway of the TrkA tyrosine kinase receptor.